An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
The myostatin/activin type II receptor (ActRII) pathway has been identified to be critical in regulating skeletal muscle size. Several other ligands, including GDF11 and the activins, signal through this pathway, suggesting that the ActRII receptors are major regulatory nodes in the regulation of muscle mass. We have developed a novel, human anti-ActRII antibody (bimagrumab, or BYM338) to prevent binding of ligands to the receptors and thus inhibit downstream signaling. BYM338 enhances differentiation of primary human skeletal myoblasts and counteracts the inhibition of differentiation induced by myostatin or activin A. BYM338 prevents myostatin- or activin A-induced atrophy through inhibition of Smad2/3 phosphorylation, thus sparing the myosin heavy chain from degradation. BYM338 dramatically increases skeletal muscle mass in mice, beyond sole inhibition of myostatin, detected by comparing the antibody with a myostatin inhibitor. A mouse version of the antibody induces enhanced muscle hypertrophy in myostatin mutant mice, further confirming a beneficial effect on muscle growth beyond myostatin inhibition alone through blockade of ActRII ligands. BYM338 protects muscles from glucocorticoid-induced atrophy and weakness via prevention of muscle and tetanic force losses. These data highlight the compelling therapeutic potential of BYM338 for the treatment of skeletal muscle atrophy and weakness in multiple settings.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“blocking these receptors can result in profound muscle growth in animals and humans18–22”
From GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates (2025) · cites this paper as [19]
In the citing paper
“Interestingly, STC2 is among the genes that are downregulated in skeletal muscle from mice following bimagrumab (activin type II receptor antagonist) treatment [149].”
From Main Pathogenic Mechanisms and Recent Advances in COPD Peripheral Skeletal Muscle Wasting (2023) · cites this paper as [149]
In the citing paper
“Myostatin is secreted by the myocytes and inhibits their differentiation and proliferation.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Myostatin and Activin receptor type 2 (ActRII) inhibitors have been developed and shown to increase muscle mass and strength and as well as improve insulin sensitivity in vitro (94, 95).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
In the citing paper
“Its level increased in individuals with sarcopenia and/or obesity.”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [95]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Bodine, S. C., Stitt, T. N., Gonzalez, M., Kline, W. O., Stover, G. L., Bauerlein, R., Zlotchenko, E., Scrimgeour, A., Lawrence, J. C., Glass, D. J., et al. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1014 · Cited by 2,752 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationDouble muscling in cattle due to mutations in the myostatin gene
McPherron, A. C., & Lee, S.-J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12457 · Cited by 2,039 · cited 1×
“In addition to myostatin (5, 6), other negative regulators of muscle mass have been reported to signal through ActRIIB, including activin A (10–13), while some uncertainty with regard to the contribution of the closely related GDF11 at regulating muscle mass and function remains (13–15).”
BackgroundRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 3×
“Prior studies had suggested this as well (10, 18), but this is the first demonstration that an antibody directed at the ActRII receptor can induce significantly greater hypertrophy than myostatin inhibition alone; the point had been made with the ActRIIB trap, but that molecule can actually also bind other ligands tha…”
BackgroundRommel, C., Bodine, S. C., Clarke, B. A., Rossman, R., Nunez, L., Stitt, T. N., Yancopoulos, G. D., & Glass, D. J. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-1009 · Cited by 1,583 · cited 1×
“This restoration of AKT phosphorylation is important, since AKT has been shown in prior studies to be required for weight-bearing-induced skeletal muscle hypertrophy; we have also previously shown that AKT activates mTOR-mediated phosphorylation of p70S6 kinase in skeletal muscle (49) and inhibits GSK3, resulting in m…”
BackgroundSelf-citationMyostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Zhou, X., Wang, J. L., Lu, J., Song, Y., Kwak, K. S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W. S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.011 · Cited by 940 · cited 3×
“Intervention at the ActRIIB pathway level under cancer cachexia conditions in mice showed a clear benefit not only for muscle preservation but also for overall survival, without affecting tumor growth (24).”
BackgroundInduction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907
Mosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Research works printed but not linked: 1
- Glass D, 2010, Curr. Top. Microbiol. Immunol., 346, 267
Cited by
Items 101–200 of 305
INVITED REVIEW: Inhibitors of myostatin as methods of enhancing muscle growth and development1
Chen, P. R., & Lee, K. (2016) · Journal of Animal Science · doi:10.2527/jas.2016-0532 · Cited by 44
Jin, Q., Qiao, C., Li, J., Xiao, B., Li, J., & Xiao, X. (2019) · Skeletal Muscle · doi:10.1186/s13395-019-0197-y · Cited by 45
Pettersen, K., Andersen, S. B., van der Veen, A., Nonstad, U., Hatakeyama, S., Lambert, C., Lach‐Trifilieff, E., Moestue, S. A., Kim, J., Grønberg, B. H., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12489 · Cited by 43
“Possibly, this relates to the ability of this antibody to block the binding of both activin A and myostatin to the ACVR2.(27,34,50) Myostatin deficiency has previously been shown to be highly anabolic.”
BackgroundSelf-citationHofbauer, L. C., Witvrouw, R., Varga, Z., Shiota, N., Cremer, M., Tanko, L. B., Rooks, D., Auberson, L. Z., Arkuszewski, M., Fretault, N., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00084-2 · Cited by 38
PTH (1–34) and growth hormone in prevention of disuse osteopenia and sarcopenia in rats
Brent, M. B., Brüel, A., & Thomsen, J. S. (2018) · Bone · doi:10.1016/j.bone.2018.02.017 · Cited by 40
Role of IGF-I in follistatin-induced skeletal muscle hypertrophy
Barbé, C., Kalista, S., Loumaye, A., Ritvos, O., Lause, P., Ferracin, B., & Thissen, J.-P. (2015) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00098.2015 · Cited by 38
“First, muscle mRNA expression and circulating concentrations of IGF-I have been reported to be increased following Mstn inhibition (35, 62, 64).”
BackgroundThe Current Landscape of Pharmacotherapies for Sarcopenia
Bahat, G., & Özkök, S. (2024) · Drugs & Aging · doi:10.1007/s40266-023-01093-7 · Cited by 48
miR‐422a suppresses SMAD4 protein expression and promotes resistance to muscle loss
Paul, R., Lee, J. Y., Donaldson, A. V. J., Connolly, M., Sharif, M. N., Natanek, S. A., Rosendahl, U., Polkey, M. I., Griffiths, M., & Kemp, P. R. (2017) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12236 · Cited by 38
Mechanisms of skeletal muscle ageing; avenues for therapeutic intervention
Lightfoot, A. P., McCormick, R., Nye, G. A., & McArdle, A. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.05.005 · Cited by 42
Animal models of cardiac cachexia
Molinari, F., Malara, N., Mollace, V., Rosano, G. M. C., & Ferraro, E. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.05.071 · Cited by 34
Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury
Magga, J. M., Vainio, L., Kilpiö, T., Hulmi, J. J., Taponen, S., Lin, R., Ramste, M. O., Szabó, Z., Gao, E., Rahtu‐Korpela, L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.013 · Cited by 33
Molecular characterization of latent GDF8 reveals mechanisms of activation
Walker, R. G., McCoy, J. C., Czepnik, M., Mills, M. J., Hagg, A., Walton, K. L., Cotton, T. R., Hyvönen, M., Lee, R. T., Gregorevic, P., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714622115 · Cited by 37
“As such, targeted inhibition of GDF8 is currently being pursued for the treatment of skeletal muscle-related disorders and associated symptoms (4, 5).”
BackgroundVoisin, S. A. C., Guilherme, J. P. L. F., Yan, X., Pushkarev, V. P., Cięszczyk, P., Massidda, M., Calò, C. M., Dyatlov, D. A., Анатольевич, К. В., Pushkareva, Y. E., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156316 · Cited by 43
“It has been shown that pharmacological blockade of the activin A signalling pathway by using soluble activin type II receptors (ligand level), or antibody to ActRII (receptor level) increases muscle and bone mass, correct anaemia or protect against diet-induced obesity [28,29].”
BackgroundAlyodawi, K., Vermeij, W. P., Omairi, S., Kretz, O., Hopkinson, M., Solagna, F., Joch, B., Brandt, R. M. C., Barnhoorn, S., van Vliet, N., et al. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12404 · Cited by 37
“13 , 14 One of the most potent reagents is the soluble activin receptor type IIB (sActRIIB) molecule, which acts to neutralize the muscle growth inhibitory properties of myostatin and activin.”
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis
Sivakumar, K., Cochrane, T. I., Sloth, B., Ashar, H., Laurent, D., Tankó, L. B., & Amato, A. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010417 · Cited by 33
Iida, H., Seki, T., Sakai, Y., Watanabe, T., Wakao, N., Matsui, H., & Imagama, S. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04143-6 · Cited by 38
“(BYM338; Novartis), a fully human monoclonal antibody that prevents ligand binding and promotes differentiation of human myoblasts [31], has shown promising results in the treatment of sarcopenia.”
BackgroundEffects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes
Garito, T., Zakaria, M., Papanicolaou, D. A., Li, Y., Pinot, P., Petricoul, O., Laurent, D., Rooks, D., Rondon, J. C., & Roubenoff, R. (2018) · Clinical Endocrinology · doi:10.1111/cen.13601 · Cited by 31
Mediators and clinical treatment for cancer cachexia: a systematic review
Cao, Z., Scott, A. M., Hoogenraad, N. J., & Osellame, L. D. (2021) · JCSM Rapid Communications · doi:10.1002/rco2.30 · Cited by 34
Luan, Y., Zhang, Y., Yu, S., You, M., Xu, P. C., Chung, S., Kurita, T., Zhu, J., & Kim, S. (2022) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12864 · Cited by 35
“Antibodies and small molecules that target activin have also been developed.(21,22) In a Phase 2 clinical trial, Bimagrumab, a human monoclonal antibody that blocks activin Type II receptors, has been shown to increase skeletal muscle mass(23)”
BackgroundDynamic Changes to the Skeletal Muscle Proteome and Ubiquitinome Induced by the E3 Ligase, ASB2β
Goodman, C. A., Davey, J. R., Hagg, A., Parker, B. L., & Gregorevic, P. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100050 · Cited by 33
“Although little is known about the role of Gbp7 in skeletal muscle, its gene expression has been found to be upregulated in a mouse model of muscle hypertrophy induced by activin/myostatin inhibition (120).”
BackgroundZmynd17 controls muscle mitochondrial quality and whole‐body metabolism
Fujita, R., Yoshioka, K., Seko, D., Suematsu, T., Mitsuhashi, S., Senoo, N., Miura, S., Nishino, I., & Ono, Y. (2018) · The FASEB Journal · doi:10.1096/fj.201701264r · Cited by 30
Cancer cachexia: molecular mechanism and pharmacological management
Li, Y., Jin, H., Chen, Y., Huang, T., Mi, Y., & Zou, Z. (2021) · Biochemical Journal · doi:10.1042/bcj20201009 · Cited by 32
Ohsawa, Y., Takayama, K., Nishimatsu, S., Okada, T., Fujino, M., Fukai, Y., Murakami, T., Hagiwara, H., Itoh, F., Tsuchida, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133713 · Cited by 33
“These inhibitors include neutralizing antibodies against the myostatin ligand [30], its type II receptors [31], and type II decoy receptors [10,32], and a small molecule that inhibits type I receptors [13].”
BackgroundShim, H. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_2 · Cited by 33
Lautaoja-Kivipelto, J. H., Pekkala, S., Pasternack, A. H., Laitinen, M., Ritvos, O., & Hulmi, J. J. (2020) · Biomolecules · doi:10.3390/biom10050695 · Cited by 30
“myostatin and GDF11 by neutralizing antibodies has attenuated cancer cachexia in vivo and muscle atrophy in vitro [13].”
BackgroundSarcopenia in chronic kidney disease: from bench to bedside
Kim, D. W., & Song, S. H. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2022.338 · Cited by 39
“Activin receptor antagonist In a mouse model, bimagrumab, a specific monoclonal antibody that binds to the activin type 2A/2B receptor, significantly promoted skeletal muscle hypertrophy [140,141].”
Mobley, C. B., Fox, C. D., Ferguson, B. S., Amin, R., Dalbo, V. J., Baier, S. M., Rathmacher, J. A., Wilson, J. M., & Roberts, M. D. (2014) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-11-38 · Cited by 31
“The MSTN treatment dosage was based upon two prior studies showing that 10–30 ng/ml reduces myotube diameter in differentiated C2C12 myotubes [36,37].”
MethodResultMatrix Metalloproteinase Responsive Delivery of Myostatin Inhibitors
Braun, A. C., Gutmann, M., Ebert, R., Jakob, F. J., Gieseler, H., Lühmann, T. C., & Meinel, L. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-2038-6 · Cited by 35
SLIT3 promotes myogenic differentiation as a novel therapeutic factor against muscle loss
Cho, H. J., Kim, H., Lee, Y., Moon, S. A., Kim, J., Kim, H., Kim, M. J., Yu, J., Kim, K., Baek, I., et al. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12769 · Cited by 32
“This efficacy is not satisfactory enough, especially compared to those of other agents currently under development.(36,37) However, the limited efficacy of SLIT3 LRRD2 may not be associated”
ResultAntibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options
Zeng, R., Glaubitz, S., & Schmidt, J. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01220-z · Cited by 29
“For preventing receptor binding of myostatin and inhibiting the negative regulation of muscle hypertrophy and muscle differentiation, a human anti-ActRII antibody, called bimagrumab, has been developed [90].”
BackgroundMuntoni, F., Byrne, B. J., McMillan, H. J., Ryan, M. M., Wong, B. L. Y., Dukart, J., Bansal, A., Cosson, V. F., Dreghici, R. D., Guridi, M., et al. (2024) · Neurology and Therapy · doi:10.1007/s40120-023-00570-w · Cited by 31
“In the phase 1 study, where participants were not on corticosteroids, 28% of healthy adult volunteers in the MAD phase presented with a low ADA titer.”
BackgroundCancer cachexia: Focus on cachexia factors and inter-organ communication
Wang, Y., Dong, Z.-K., An, Z., & Jin, W. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002846 · Cited by 27
“[173] Another humanized anti-ActRIIB antibody, LY2495655, has been tested in phase II study involving patients with pancreatic cancer, although no clinical benefits have been observed.”
BackgroundCellular and molecular modulation of rotator cuff muscle pathophysiology
Fu, C., Huang, A. H., Galatz, L. M., & Han, W. M. (2021) · Journal of Orthopaedic Research® · doi:10.1002/jor.25179 · Cited by 24
A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice
Wang, Q., Guo, T., Portas, J., & McPherron, A. C. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10430 · Cited by 25
“MSTN-/- mice or mice injected with an antibody that recognizes ACVR2 and ACVR2B are resistant to dexamethasone-induced muscle atrophy (79,80).”
BackgroundLodberg, A., van der Eerden, B. C. J., Boers-Sijmons, B., Thomsen, J. S., Brüel, A., van Leeuwen, J. P. T. M., & Eijken, M. (2019) · The FASEB Journal · doi:10.1096/fj.201801969rr · Cited by 25
“Inhibitors of the activin receptor signaling pathway (IASPs) are based on various approaches, including: 1) soluble decoy receptors that trap ligands extracellularly and consist ofActRIIAorActRIIB ectodomains fusedwith the Fc portion of human IgG1 (13, 14); 2) neutralizing antibodies, peptibodies, or adnectins against…”
BackgroundLahouti, A. H., Amato, A. A., & Christopher‐Stine, L. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000116 · Cited by 24
“Bimagrumab prevents binding of ligands to this receptor (such as myostatin and activin) and can induce significantly greater hypertrophy of the muscle than myostatin inhibition alone [33].”
BackgroundGonzalez Trotter, D., Donahue, S., Wynne, C., Ali, S., Parasoglou, P., Boyapati, A., Mohammadi, K., Musser, B. J., Meier, P., Mastaitis, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59380-3 · Cited by 23
“However, studies in mice showed that receptor blockade had about twice the impact on muscle growth compared to GDF8 blockade 9 , suggesting that there may be other negative regulators of muscle mass acting via these receptors; with greater ef fi cacy came greater concerns about adverse events with…”
Self-citationWalpurgis, K., Thomas, A., Dellanna, F., Schänzer, W., & Thevis, M. (2018) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201700120 · Cited by 24
Bone and morphogenetic protein signalling and muscle mass
Sartori, R., & Sandri, M. (2015) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000172 · Cited by 22
“In fact, they interact not only with BMPRII but also ActRIIB/IIA, and therefore, the administration of soluble ActRII receptors [30], or ActRII antagonists [33] may introduce the unintended risk of simultaneously blocking/altering the positive effects of BMP ligands.”
BackgroundBéchir, N., Pecchi, É., Vilmen, C., Fur, Y. L., Amthor, H., Bernard, M., Bendahan, D., & Giannesini, B. (2016) · The FASEB Journal · doi:10.1096/fj.201600271rr · Cited by 23
Activin A Causes Muscle Atrophy through MEF2C-Dependent Impaired Myogenesis
Loumaye, A., Lause, P., Zhong, X., Zimmers, T. A., Bindels, L. B., & Thissen, J. (2022) · Cells · doi:10.3390/cells11071119 · Cited by 25
Regulation of Hspb7 by MEF2 and AP-1: implications for Hspb7 in muscle atrophy
Tobin, S. W., Yang, D., Girgis, J., Farahzad, A., Blais, A., & McDermott, J. C. (2016) · Journal of Cell Science · doi:10.1242/jcs.190009 · Cited by 27
“A new antibody recently characterized to bind to both members (A and B) of the myostatin/activin type II receptor (ActRII) induces hypertrophy in a muscle wasting model in vivo (Lach-Trifilieff et al., 2014).”
BackgroundBioorthogonal Modification of Cell Derived Matrices by Metabolic Glycoengineering
Gutmann, M., Braun, A. C., Seibel, J., & Lühmann, T. C. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00264 · Cited by 28
Emerging Treatment Options for Sarcopenia in Chronic Liver Disease
Kim, Y. (2021) · Life · doi:10.3390/life11030250 · Cited by 26
Novel investigational biologics for the treatment of cancer cachexia
JOSEPH, D. R., Heavey, S. F., Revta, C., & Roeland, E. J. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.907788 · Cited by 23
“Dose-dependent recovery of skeletal muscle mass was observed after 2 weekly doses [51].”
BackgroundMethodInfluentialLow Myostatin Serum Levels Are Associated with Poor Outcome in Critically Ill Patients
Wirtz, T. H., Loosen, S. H., Buendgens, L., Kurt, B., Jhaisha, S. A., Hohlstein, P., Brozat, J. F., Weiskirchen, R., Luedde, T., Tacke, F., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10080574 · Cited by 24
“The human monoclonal antibody bimagrumab binds to Activin receptor type 2, thereby inhibiting the interaction of the ligands Myostatin with Activin resulting in skeletal muscle hypertrophy [32,33].”
BackgroundKruszewski, M., & Kruszewski, M. (2022) · Genes · doi:10.3390/genes13112055 · Cited by 31
Manfredi, L. H., Ang, J., Peker, N., Dagda, R. K., & McFarlane, C. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00516.2018 · Cited by 21
Alterations in pectoralis muscle cell characteristics after radiation of the human breast in situ
Wallner, C., Drysch, M., Hahn, S. A., Becerikli, M., Puscz, F., Wagner, J. M., Sacher, M., Sogorski, A., Dadras, M., Lehnhardt, M., et al. (2019) · Journal of Radiation Research · doi:10.1093/jrr/rrz067 · Cited by 22
“Bimagrumab is an activin type II receptor antagonist (target of myostatin) intended to be used in patients after hip replacement or patients with general muscle cachexia to reduce muscle catabolism [26,27].”
BackgroundThe Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
The TGFβ superfamily in cardiac dysfunction
Wu, J., Jackson‐Weaver, O., & Xu, J. (2018) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmy007 · Cited by 20
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
Pétricoul, O., Nazarian, A., Schuehly, U., Schramm, U., David, O. J., Laurent, D., Præstgaard, J., Roubenoff, R., Papanicolaou, D. A., & Rooks, D. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01189-0 · Cited by 20
“3 pM) to human ActRIIB and with relatively lower affinity to human ActRIIA (KD 434 ± 25 pM) [3].”
BackgroundActivation of β-catenin in mesenchymal progenitors leads to muscle mass loss
Kajabadi, N., Low, M., Jacques, E., Lad, H., Tung, L. W., Babaeijandaghi, F., Gamu, D., Zelada, D., Wong, C. K., Chang, C.-K., et al. (2023) · Developmental Cell · doi:10.1016/j.devcel.2023.02.009 · Cited by 23
Salzler, R. R., Shah, D., Dore, A. T., Bauerlein, R., Miloscio, L., Latres, E., Papadopoulos, N. J., Olson, W. C., MacDonald, D., & Duan, X. (2016) · PROTEOMICS · doi:10.1002/pmic.201600006 · Cited by 45
Koziczak‐Holbro, M., Rigel, D. F., Dumotier, B. M., Sykes, D. A., Tsao, J., Nguyen, N., Bösch, J., Jourdain, M., Flotte, L., Adachi, Y., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255307 · Cited by 20
Self-citationWalpurgis, K., Thomas, A., & Thevis, M. (2019) · Drug Testing and Analysis · doi:10.1002/dta.2729 · Cited by 20
“They comprise drug candidates specifically targeting the cytokine such as anti-myostatin antibodies,(12) peptibodies,(13) adnectin- and follistatin-Fc fusion proteins,(14,15) and agents derived from the myostatin propeptide,(16,17) as well as multi-target approaches such as receptor competitors(18) and anti-ActRII ant…”
BackgroundAre we giving too much weight to lean mass loss?
Bolte, J., Smelter, A. A., & Norton, L. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102253 · Cited by 22
“In preclinical models, bimagrumab was shown to increase muscle mass, enlarge myotube diameter, and both prevent and reverse glucocorticoid-induced atrophy in mice [206].”
Cancer Cachexia: Signaling and Transcriptional Regulation of Muscle Catabolic Genes
Rao, V. K., Das, D., & Taneja, R. (2022) · Cancers · doi:10.3390/cancers14174258 · Cited by 23
“In humans, phase I and II trials on cancer patients with ALD518, a humanized IL-6 antibody developed to treat cachexia was found to be safe and well tolerated [72].”
BackgroundBrauwers, B., Machado, F. V. C., Beijers, R. J. H. C. G., Spruit, M. A., & Franssen, F. M. E. (2023) · Nutrients · doi:10.3390/nu15245136 · Cited by 22
Chen, P. R., Suh, Y., Shin, S., Woodfint, R. M., Hwang, S., & Lee, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184617 · Cited by 28
TGF-β Pathway Inhibition Protects the Diaphragm From Sepsis-Induced Wasting and Weakness in Rat
Jude, B., Tissier, F., Dubourg, A., Droguet, M., Castel, T., Léon, K., Giroux‐Metges, M., & Pennec, J. (2019) · Shock · doi:10.1097/shk.0000000000001393 · Cited by 18
“Activin A was previously shown to increase SMAD3 phosphorylation as well as to decrease PI3K phosphorylation, leading to muscle atrophy and the inhibition of ActRIIB which usually protects muscle from atrophy induced by glucocorticoid stimulation with dexamethasone (9).”
BackgroundSkrzypczak, D., Skrzypczak-Zielińska, M., Ratajczak, A. E., Szymczak‐Tomczak, A., Eder, P., Słomski, R., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2021) · Biomedicines · doi:10.3390/biomedicines9101301 · Cited by 21
“BYM-338 may also counteract glucocorticosteroid-induced muscle atrophy, which could be promising for IBD cases where glucocorticosteroids are used to treat the exacerbations of the disease [75,76].”
BackgroundKaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0065 · Cited by 18
Discovery of artificial VIPR2-antagonist peptides possessing receptor- and ligand-selectivity
Sakamoto, K., Koyama, R., Kamada, Y., Miwa, M., & Tani, A. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.144 · Cited by 16
Sarcopenic obesity in the Asia-Pacific region: Epidemiology, risk factors, and management
Huang, C., & Wu, C. (2025) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2025.05.001 · Cited by 21
“Bimagrumab is a pharmaceutical agent that targets ActRII to combat obesity [126].”
The inflammatory response, a mixed blessing for muscle homeostasis and plasticity
Bouredji, Z., Argaw, A., & Frenette, J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1032450 · Cited by 21
“In cachexia-associated muscle atrophy, the pharmacological blockade of myostatin/activin has been found to be the most effective therapy (Estelle et al., 2014).”
BackgroundPrajapati, P., Kumar, A., Chaudary, R., Mangrulkar, S. V., Arya, M., & Kushwaha, S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467216666230308142137 · Cited by 24
Mechanisms of BMP–Receptor Interaction and Activation
Mueller, T. D. (2015) · Vitamins and hormones · doi:10.1016/bs.vh.2015.06.003 · Cited by 19
Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth
Jin, Q., Qiao, C., Li, J., Li, J., & Xiao, X. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.016 · Cited by 15
Lodberg, A., Eijken, M., van der Eerden, B. C. J., Okkels, M. W., Thomsen, J. S., & Brüel, A. (2018) · Bone · doi:10.1016/j.bone.2018.02.026 · Cited by 15
Formicola, L., Pannérec, A., Correra, R. M., Gayraud-Morel, B., Ollitrault, D., Besson, V., Tajbakhsh, S., Lachey, J. L., Seehra, J. S., Marazzi, G., et al. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00515 · Cited by 18
GrönholdtKlein, M., Altun, M., Becklén, M., Kahm, E. D., Fahlström, A., Rullman, E., & Ulfhake, B. (2019) · Acta Physiologica · doi:10.1111/apha.13335 · Cited by 20
Sachdev, R., Kappes‐Horn, K., Paulsen, L., Duernberger, Y., Pleschka, C., Denner, P., Kundu, B., Reimann, J., & Vorberg, I. M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0997-9 · Cited by 16
“Recently, a late-phase clinical trial of the ActRIIB receptor antibody BYM338 [79] in sIBM patients failed to demonstrate efficacy, suggesting that ActRIIB receptor signaling is not a major contributor to muscle atrophy in sIBM (https://www.”
BackgroundStructures of activin ligand traps using natural sets of type I and type II TGFβ receptors
Goebel, E. J., Kattamuri, C., Gipson, G. R., Krishnan, L., Chavez, M., Czepnik, M., Maguire, M. C., Grenha, R., Håkansson, M., Logan, D. T., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103590 · Cited by 15
ActivinA activates Notch1-Shh signaling to regulate proliferation in C2C12 skeletal muscle cells
Ma, L., Li, C., Lian, S., Xu, B., Yuan, J., Lu, J., Yang, H., Guo, J., & Ji, H. L. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.111055 · Cited by 16
Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions
Thomasius, F. E., Pesta, D. H., & Rittweger, J. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15877 · Cited by 17
“133,136,137 While these trials show that both signalling molecules are involved in regulating muscle growth, it also became evident that activin A is possibly more important in humans compared to mice.”
Sharma, G., Banerjee, R., & Srivastava, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c07480 · Cited by 14
Insights into Muscle Degeneration from Heritable Inclusion Body Myopathies
Krause, S. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00013 · Cited by 13
“An encouraging approach is a novel strategy to promote muscle maintenance and delay muscular atrophy by utilizing an antibody, which modulates the activin type II receptor (ActRII) response (Lach-Trifilieff et al., 2014).”
Maricelli, J. W., Bishaw, Y. M., Wang, B., Du, ., & Rodgers, B. D. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.158 · Cited by 14
Walpurgis, K., Thomas, A., Schänzer, W., & Thevis, M. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500043 · Cited by 14
Emerging therapeutic options for sporadic inclusion body myositis
Alfano, L. N., & Lowes, L. P. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s65368 · Cited by 13
“in the myostatin pathway to potentially increase muscle size in patients with IBM.(93) Initial results of a safety study”
Vaughan, D., Ritvos, O., Mitchell, R., Kretz, O., Lalowski, M. M., Amthor, H., Chambers, D., Matsakas, A., Pasternack, A. H., Collins‐Hooper, H., et al. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2019.8737 · Cited by 12
Therapeutic effects of androgens for cachexia
Giovanelli, L., & Quinton, R. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101598 · Cited by 15
Critical analytical evaluation of promising markers for sarcopenia
Cavalier, E., Beaudart, C., Buckinx, F., Bruyère, O., & Reginster, J.-Y. (2016) · European Geriatric Medicine · doi:10.1016/j.eurger.2015.11.002 · Cited by 12
“These markers have been chosen because they play a role in the linkage of muscle to bone [5–7], are associated with lean mass [8] or are regulators of muscle mass [9–11].”
BackgroundGDF11 and aging biology - controversies resolved and pending
Driss, L. B., Lian, J., Walker, R. G., Howard, J. A., Thompson, T. B., Rubin, L. L., Wagers, A. J., & Lee, R. T. (2023) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.23 · Cited by 15
Advancements in Drug Delivery Systems for the Treatment of Sarcopenia: An Updated Overview
Najm, A., Moldoveanu, E.-T., Niculescu, A.-G., Grumezescu, A. M., Beuran, M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910766 · Cited by 13
Bromer, F. D., Lodberg, A., Eijken, M., Andersen, C. B. F., Poulsen, M. F., Thomsen, J. S., & Brüel, A. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13718 · Cited by 13
Tankó, L. B., Goldhahn, J., Varela, A., Lesage, E., Smith, S. Y., Pilling, A. M., & Chivers, S. (2016) · Calcified Tissue International · doi:10.1007/s00223-016-0148-0 · Cited by 13
“The more rapid and marked increases in body weight in bimagrumab-treated versus vehicle-treated animals were similar to those previously reported in mice [5], which was attributed to muscular hypertrophy in line with the strong promyogenic effect of ActRII attenuation [4].”
InfluentialBrent, M. B., Lodberg, A., Bromer, F. D., van der Eerden, B. C. J., Eijken, M., Brüel, A., & Thomsen, J. S. (2020) · Bone · doi:10.1016/j.bone.2020.115692 · Cited by 12
Meyer, G. A., & Ward, S. R. (2016) · Physical Therapy · doi:10.2522/ptj.20150029 · Cited by 14
Advances in understanding COPD
Anderson, G. P. (2016) · F1000Research · doi:10.12688/f1000research.7018.1 · Cited by 17
Emerging Interventions for Elderly Patients—The Promise of Regenerative Medicine
Miller, R. R., & Roubenoff, R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1272 · Cited by 12
“In mouse models, the murine version of bimagrumab demonstrated a greater increase in body weight and muscle size when compared with a myostatin inhibitor.(29) In older adults with sarcopenia administered bimagrumab over 16 weeks, significant increases in thigh muscle volume of 7.”
BackgroundMyostatin serum concentration as an indicator for deviated muscle metabolism in severe burn injuries
Wallner, C., Wagner, J. M., Dittfeld, S., Drysch, M., Lehnhardt, M., & Behr, B. (2018) · Scandinavian Journal of Surgery · doi:10.1177/1457496918812230 · Cited by 11
Béchir, N., Pecchi, É., Relizani, K., Vilmen, C., Fur, Y. L., Bernard, M., Amthor, H., Bendahan, D., & Giannesini, B. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2015 · Cited by 11
“These approaches mainly include the systemic delivery of neutralizing antibodies against ActRIIB or myostatin (31, 36), and injection of a soluble recombinant form of ActRIIB (sActRIIB-Fc), which acts as a decoy receptor disrupting the interaction of endogenous ActRIIB receptor with its ligands (5, 38, 44).”
BackgroundDucata, D. D., Jaehrling, J., Hänel, C., Satzger, M., Wolber, M., Ostendorp, R., Pabst, S., & Brocks, B. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115595002 · Cited by 11
A skeletal muscle atlas shows neuromuscular junction adaptations to growth and atrophy
Campanario, S., Grima-Terrén, M., Rommelfanger, M., Orso, S. D., Feng, X., Cisneros, A., Ramírez‐Pardo, I., Calls, A., Yang, B. A., Ko, K. D., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.03.010 · Cited by 12
Schellino, R., Boido, M., Vrijbloed, J. W., Fariello, R. G., & Vercelli, A. (2023) · Aging and Disease · doi:10.14336/ad.2023.0713-1 · Cited by 12
Vestal, K. A., Kattamuri, C., Koyiloth, M., Ongaro, L., Howard, J. A., Deaton, A. M., Ticau, S., Dubey, A., Bernard, D. J., & Thompson, T. B. (2024) · Biochemical Journal · doi:10.1042/bcj20230404 · Cited by 10
An update on pharmacotherapeutic strategies for obesity
Tchang, B. G., Tarazi, M. S., Aras, M., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888927 · Cited by 12
Cancer cachexia: towards integrated therapeutic interventions
Molfino, A., Formiconi, A., Fanelli, F. R., & Muscaritoli, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.939068 · Cited by 10
“This led investigators to suggest the use of the fully human anti-ActRII monoclonal antibody bimagrumab (BYM338) [13].”
Background
Metadata
- Authors
- Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., Hatakeyama, S., & Glass, D. J.
- Affiliations
- MusculoSkeletal Diseases, Novartis Institutes for Biomedical Research, Basel, Switzerland
- Novartis (Switzerland) (CH)
- Development and Molecular Pathways, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
- Novartis Institutes for BioMedical Research (CH)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2014-02-01
- Volume
- 34
- Issue
- 4
- Pages
- 606-618
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC3911487
- OpenAlex
- W2102107385
- Semantic Scholar
- 9ec58206f235e018d6953a27e975ae19a1c51271
- Cited by
- 306
- References
- 58
- Citations by year
- 2026: 22 · 2025: 16 · 2024: 19 · 2023: 21 · 2022: 20 · 2021: 37 · 2020: 29 · 2019: 28 · 2018: 25 · 2017: 18 · 2016: 29 · 2015: 21 · 2014: 19
- FWCI
- 10.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis
- MorphoSys
- Novartis Pharma
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- activin type II receptor, bimagrumab, myostatin, skeletal muscle hypertrophy, muscle atrophy, Smad2/3 phosphorylation, skeletal myoblast differentiation, activin A, GDF11, muscle weakness, myosin heavy chain degradation, muscle mass regulation
- MeSH terms
- Animals, Antibodies, Monoclonal, Atrophy, Cell Differentiation, Humans, Hypertrophy, Signal Transduction, Muscle, Skeletal, Antibodies, Blocking, Activins, Activin Receptors, Type II, Myoblasts, Skeletal, Mice, Smad2 Protein, Smad3 Protein, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.